Targeting cysteine proteases in trypanosomatid disease drug discovery
- 1 December 2017
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 180, 49-61
Abstract
No abstract availableKeywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2013/07600-3, 2013/25658-9)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (465637/2014-0)
This publication has 67 references indexed in Scilit:
- Chagas’ DiseaseNew England Journal of Medicine, 2015
- Cruzipain: An Update on its Potential as Chemotherapy Target against the Human Pathogen Trypanosoma cruziCurrent Medicinal Chemistry, 2015
- Fexinidazole: A Potential New Drug Candidate for Chagas DiseasePLOS Neglected Tropical Diseases, 2012
- Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Médecins Sans Frontières Experience in the Democratic Republic of the CongoClinical Infectious Diseases, 2012
- Urbanisation and infectious diseases in a globalised worldThe Lancet Infectious Diseases, 2011
- RNA Interference of Trypanosoma brucei Cathepsin B and L Affects Disease Progression in a Mouse ModelPLOS Neglected Tropical Diseases, 2008
- Sulfates are main targets of immune responses to cruzipain and are involved in heart damage in BALB/c immunized miceInternational Immunology, 2008
- The Genome of the African Trypanosome Trypanosoma bruceiScience, 2005
- Specific cleavage sites on human IgG subclasses by cruzipain, the major cysteine proteinase from Trypanosoma cruziMolecular and Biochemical Parasitology, 2003
- The Protein Data BankNucleic Acids Research, 2000